|
|
|
| Prevention and control strategy of COVID-19 in the vaccine era |
| CHEN Enfu
|
| Department of Communicable Disease Control and Prevention, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang 310051, China |
|
|
|
|
Abstract Globally, non-pharmacological interventions, such as keeping social distance and wearing masks, are the primary prevention and control strategy in the early stage of the coronavirus disease 2019 (COVID-19) pandemic. The successful development and the urgency use of the COVID-19 vaccines in some countries brings a new stage of combining immunization with non-pharmacological interventions in the fight with COVID-19. For the shortage of vaccines, the immunization strategies vary in countries. To end the pandemic, 47%-85% of the population should be immunized with effective COVID-19 vaccines, thus we should boost the yield of vaccines, formulate scientific immunization strategies, promote the mass immunization, improve the willingness of vaccination, and increase the equity of vaccine allocation; meanwhile, we should strengthen the surveillance of virus variation, vaccine effectiveness and safety, and keep on the vaccine research to copy with the potential threat of the virus variation.
|
|
Received: 05 February 2021
Revised: 02 March 2021
Published: 16 March 2021
|
|
|
|
|
|
[1] World Health Organization.Weekly epidemiological update-19 January 2021[EB/OL] .(2021-01-19)[2021-03-02] .https://www.who.int/publications/m/item/weekly-epidemiological-update---19-january-2021.
[2] 林君芬,吴梦娜,吴昊澄,等. 浙江省新型冠状病毒肺炎病例流行特征分析[J] . 预防医学,2020,32(3):217-221,225.
[3] SARKAR A,LIU G,JIN Y,et al.Public health preparedness and responses to the coronavirus disease 2019 (COVID-19) pandemic in South Asia:a situation and policy analysis[J] . Glob Health J,2020,4(4):121-132.
[4] SJODIN H,WILDER-SMITH A,OSMAN S,et al.Only strict quarantine measures can curb the coronavirus disease(COVID-19)outbreak in Italy, 2020[J] . Euro Surveill,2020,25(13):2000280.
[5] CHATTERJEE P,NAGI N,AGARWAL A,et al.The 2019 novel coronavirus disease(COVID-19)pandemic: a review of the current evidence[J] .Indian J Med Res,2020,151(2/3):147-159.
[6] 吴丹,郑徽,李艺星,等. 群体免疫及其对传染病防控的意义[J] .中国疫苗和免疫,2020,26(4):123-127.
[7] 吴尊友. 群体免疫作为新型冠状病毒肺炎防控策略可行性分析[J] .中华流行病学杂志,2020,41(7):986-989.
[8] World Health Organization.Draft landscape and tracker of COVID-19 candidate vaccines[EB/OL] .(2021-02-23)[2021-03-02] .https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
[9] 朱瑶,韦意娜,孙畅,等.新型冠状病毒肺炎疫苗研究进展[J] .预防医学,2021,33(2):143-148.
[10] Medicines and Healthcare Products Agency. Regulatory approval of Pfizer/BioNTech vaccine for COVID-19[EB/OL] .(2021-01-28)[2021-03-02] .https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19.
[11] Medicines and Healthcare Products Agency.Regulatory approval of COVID-19 Vaccine AstraZeneca[EB/OL] .(2021-02-23)[2021-03-02] .https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca.
[12] Medicines and Healthcare Products Agency.Regulatory approval of COVID-19 Vaccine Moderna[EB/OL] .(2021-02-19)[2021-03-02] .https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-moderna.
[13] UK Government.Vaccinations in United Kingdom[EB/OL] . (2021-02-24)[2021-03-02] . https://coronavirus.data.gov.uk/details/vaccinations.
[14] OLIVER S,GARGANO J,MARIN M,et al.The Advisory Committee on Immunization Practices＇interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine — United States,December 2020[J] . MMWR,2020,69(50):1922-1924.
[15] ANESI J.The Advisory Committee on Immunization Practices＇updated interim recommendation for allocation of COVID 19 vaccine—United states,December 2020[J] .Am J Transplant,2021,21(2):897.
[16] Centers for Disease Control and Prevention. COVID-19 vaccinations in the United States[EB/OL] . (2021-02-23)[2021-03-02] . https://covid.cdc.gov/covid-data-tracker/#vaccinations.
[17] European Center for Disease Control and Prevention. COVID-19 vaccine tracker[EB/OL] . (2021-02-19) [2021-03-02] . https://qap.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab.
[18] 国药集团中国生物新冠灭活疫苗获批附条件上市[EB/OL] . [2021-03-02] . http://www.sinopharm.com/s/1223-4126-38840.html.
[19] Sinovac receives conditional marketing authorization in China for its COVID-19 vaccine[EB/OL] .(2021-02-28)[2021-03-02] .http://www.sinovacbio.com/?optionid=754&auto_id=923.
[20] 中华人民共和国国家药品监督管理局.国家药监局附条件批准国药中生武汉公司新型冠状病毒灭活疫苗(Vero细胞)注册申请[EB/OL] .(2021-02-25)[2021-03-02] .https://www.nmpa.gov.cn/yaowen/ypjgyw/20210225184306142.html.
[21] 中华人民共和国国家药品监督管理局.国家药监局附条件批准康希诺生物股份公司重组新型冠状病毒疫苗(5型腺病毒载体)注册申请[EB/OL] .(2021-02-25)[2021-03-02] .https://www.nmpa.gov.cn/yaowen/ypjgyw/20210225184523188.html.
[22] Health Sciences Authority Singapore.HSA grants interim authorisation for first COVID-19 vaccine in Singapore[EB/OL] .(2020-12-14)[2021-03-02] .https://www.hsa.gov.sg/announcements/press-release/interimauth-firstcovid19vaccine.
[23] Health Sciences Authority Singapore.HSA grants interim authorisation for Moderna COVID-19 vaccine in Singapore[EB/OL] .(2021-02-03)[2021-03-02] .https://www.hsa.gov.sg/announcements/press-release/hsa-grants-interim-authorisation-for-moderna-covid-19-vaccine-in-singapore.
[24] Pacific Daily News. Japan approves first vaccine,less than six months before Tokyo Olympics[EB/OL] .(2021-02-16) [2021-03-02] .https://www.guampdn.com/story/money/2021/02/16/japan-approves-first-covid-19-vaccine/6759064002.
[25] World Health Organization.Coronavirus(COVID-19)vaccinations[EB/OL] .(2021-02-23)[2021-03-02] .https://ourworldindata.org/covid-vaccinations.
[26] World Health Organization.Coronavirus disease(COVID-19):virus evolution. (2020-12-30) [2021-03-02] .Coronavirus disease(COVID-19):virus evolution. (2020-12-30) [2021-03-02] .http://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answer.
[27] GRUBAUGH N D,HANAGE W P,RASMUSSEN A L.Making sense of mutation:what D614G means for the COVID-19 pandemic remains unclear[J] .Cell,2020,182(4):794-795.
[28] SAHA P,BANERJEE A K,TRIPATHI P P,et al. A virus that has gone viral:amino acid mutation in S protein of Indian isolate of Coronavirus COVID-19 might impact receptor binding,and thus,infectivity[J] . Biosci Rep,2020,40(5):BSR20201312.
[29] CONTI P,CARAFFA A,GALLENGA C E,et al.The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem[J] . J Biol Regul Homeost Agents,2021,35(1):33377359.
[30] SHI P Y,XIE X P,ZOU J,et al. Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera [J/OL] . BioRxiv(2021-01-07)[2021-03-02] .https://www.researchgate.net/publication/348505823_Neutralization_of_N501Y_mutant_SARS-CoV-2_by_BNT162b2_vaccine-elicited_sera.
[31] 张田勘. 中国人接种新冠疫苗意愿最高[J] .中国老年,2020(20):40.
[32] 李晶,敖纳,尹建华,等.昆明市门诊患者新型冠状病毒疫苗接种意愿及影响因素分析[J/OL] .中国公共卫生[2021-03-02] .http://www.zgggws.com/fileZGGGWSCN/journal/article/zgggws/newcreate/1133368.pdf.
[33] KREPS S,PRASAD S,BROWNSTEIN J S,et al.Factors associated with US adults＇likelihood of accepting COVID-19 vaccination[J] .JAMA Netw Open,2020,3(10):e2025594.
[34] Center for Disease Control and Prevention.COVID-19 vaccine information for specific groups[EB/OL] .(2021-02-04)[2021-03-02] .https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/specific-groups.html.
[35] European Center for Disease Control and Prevention.ECDC releases COVID-19 vaccination rollout strategies for EU/EEA[EB/OL] .(2020-12-20)[2021-03-02] .https://www.ecdc.europa.eu/en/news-events/ecdc-releases-vaccination-rollout-strategies-eueea.
[36] 周文. 中国加入新冠疫苗实施计划超过180个国家和地区承诺加入,占全球人口总量的90%[J] .人民周刊,2020(19):12.
[37] GAO G F.COVID-19:a year long and beyond?[J] .China CDC Weekly,2021,3(8):157-158.
[38] 武汉生活网.中国新冠灭活疫苗一年能生产多少支,新冠疫苗产量多少?[EB/OL] .(2021-01-06)[2021-03-02] .http://www.wuhan.com/xinwen/61681.html.
[39] HUANG B,WANG J,CAI J,et al.Integrated vaccination and physical distancing interventions to prevent future COVID-19 waves in Chinese cities[J/OL] .Nat Hum Behav(2021-02-18)[2021-03-02] .https://www.ncbi.nlm.nih.gov/pubmed/33603201.
[40] MADI N,ALTAWALAH H,ALFOUZAN W,et al.Assessment of immune status against measles,mumps,and rubella in young Kuwaitis:MMR vaccine efficacy[J] .J Med Virol,2020,92(8):963-970.
[41] PLEGUEZUELOS O,DILLE J,DE GROEN S,et al.Immunogenicity,safety,and efficacy of a standalone universal influenza vaccine,FLU-v,in healthy adults:a randomized clinical trial[J] .Ann Intern Med,2020,172(7):453-462. |
|
|
|
